Canagliflozin With Gemcitabine in Pancreatic Carcinoma

NANot yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

March 31, 2027

Conditions
Pancreatic Cancer
Interventions
DRUG

Canagliflozin and Gemcitabine

"on the first, 8th and 15th day of treatment, patients were given intravenous drip of 1000mg/m2 gemcitabine, and 21 days was a course of treatment, lasting for 6 courses.~Take 400mg canagliflozin orally every day, and continue to use it until the end of chemotherapy. According to the patient's tolerance to disulfiram, the dose of canagliflozin can be re-evaluated during the treatment, and the highest dose is 125mg per day. The clinical symptoms, signs and adverse reactions of patients were observed, and the treatment effect of patients was evaluated after two consecutive cycles with 4 weeks as a cycle"

DRUG

Gemcitabine

on the first, 8th and 15th day of treatment, patients were given 1000mg/m2 gemcitabine intravenously, and 21 days was a course of treatment, lasting for 6 courses.

Trial Locations (1)

310000

Hangzhou first people's Hospital, Hangzhou

All Listed Sponsors
collaborator

College of Pharmaceutical Sciences at Zhejiang University

UNKNOWN

collaborator

The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University

UNKNOWN

lead

Zhang Xiaofeng,MD

OTHER

NCT05903703 - Canagliflozin With Gemcitabine in Pancreatic Carcinoma | Biotech Hunter | Biotech Hunter